OASMY (Vivesto AB) Current Deferred Revenue : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Vivesto AB's current deferred revenue for the quarter that ended in Mar. 2025 was $0.00 Mil.

Vivesto AB Current Deferred Revenue Historical Data

The historical data trend for Vivesto AB's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB Current Deferred Revenue Chart

Vivesto AB Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Dec24

Current Deferred Revenue

Get a 7-Day Free Trial

Vivesto AB Quarterly Data
	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Deferred Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Vivesto AB Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Vivesto AB's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivesto AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » Current Deferred Revenue

Traded in Other Exchanges

VIVE:Sweden 0N4A:UK OMAX:Germany

Address

Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73

Website

https://www.vivesto.com

Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.